Fujifilm completes acquisition of Shenandoah Biotechnology
TOKYO: FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announces that FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for life science research, bioproduction, and cell therapy manufacturing, completed the acquisition of Shenandoah Biotechnology, Inc., a leading…
Fujifilm to acquire Shenandoah Biotechnology, leading manufacturer of recombinant proteins
The acquisition offers customers worldwide a single point of access for cGMP cell culture solutions for biopharmaceuticals, and cell and gene therapies.
Closed Loop Medicine announces completion of Precision Medicine Clinical Trial for patients with high blood pressure
Cambridge and London: Closed Loop Medicine Ltd, a leader in the development of single prescription drug plus digital therapy (DTx) combination products to enable precision dosing and care, announces that the last patient has completed participation in a clinical trial investigating the Company’s integrated precision care product solution for patients with hypertension.
Avacta appoints Dr Christina Coughlin as Non-Executive Director
Cambridge and Wetherby: Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces the appointment of Christina Coughlin, M.D., Ph.D., as Non-executive Director to the Board with immediate effect.
ELRIG UK establishes Scientific Advisory Board
York, UK: The European Laboratory Research & Innovation Group (ELRIG) UK announces the formation of its Scientific Advisory Board (SAB) with the appointment of senior drug discovery experts: Dr Chas Bountra OBE, Dr Richard Eglen, Steve Rees OBE, Dr Cathy Tralau-Stewart, and Dr Ian Waddell.
Flow Eighteen38 receives €5 million EUR (c.$5.58 million USD) to expand production and biophysical capabilities
Porto, Portugal, Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, today announced a €5 million EUR (c.$5.58 million USD) investment into its protein production and biophysical characterization capabilities and services from its parent company, FairJourney Biologics S.A. (FJB), leaders in the discovery…
Orbit Discovery and WuXi AppTec sign agreement to access peptide discovery and optimisation technologies
Oxford, United Kingdom, Orbit Discovery (Orbit), a ground-breaking peptide discovery company, announces the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry.
Gyros Protein Technologies introduces PurePep Sonata+ peptide synthesizer
Uppsala, Sweden: Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, today announced the launch of PurePep® Sonata®+, a mid-pilot scale peptide synthesizer. The new system is an upgraded version of the Company’s previous model, Sonata® XT, known for its reliability and robustness, to further strengthen the…
Evonetix demonstrates novel enzymatic DNA synthesis method
EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has achieved enzymatic DNA synthesis capability with its proprietary, thermally controlled synthesis chemistry.
Optibrium adds augmented intelligence for compound design to its StarDrop small molecule drug discovery software
Optibrium Ltd, a leading developer of software for drug discovery, today announced the release of the latest version of StarDrop™, its comprehensive software platform for small molecule design, optimisation and data analysis.
Dotmatics releases Platform 22.1 - delivering new capabilities to streamline lab workflows
Latest Platform delivers new capabilities to streamline lab workflows and support customers’ data-informed decision making.
Centauri Therapeutics closes £24 million GBP Series A investment round
Centauri Therapeutics Limited (Centauri), an immunotherapy company founded by Animatrix Founders LLP and focused on the treatment of infectious diseases, announces the close of its £24 million GBP (c. 32 million USD) Series A investment round.
OxDX raises £2.6M pre-seed funding to develop AI powered rapid diagnostic technology
Technology aims to improve speed, cost and accuracy of infectious disease diagnostics. The funding will be used to expand team and further validate technology.
Bio-Rad introduces anti-daratumumab antibodies
Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced the launch of a range of anti-daratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38.
Enterprise Therapeutics appoints Dr Niyati Prasad as Chief Medical Officer
Dr Prasad will lead Enterprise’s development strategy to support the continued advancement of the Company’s respiratory programmes through the clinic.
Phico Therapeutics establishes Scientific Advisory Board
SAB will provide scientific oversight and strategic advice to support the progression Phico’s engineered phage antibacterial therapy, SASPject, through clinical trials.
Bio-Rad launches Anti-Pertuzumab Antibodies
Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, introduces four inhibitory antibodies that are highly specific to pertuzumab (Perjeta).
Antiverse collaborates with top 20 pharma company to identify antibody drug candidates using AI Augmented Drug Discovery platform
Antiverse’s platform accurately identified diverse and rare antibodies. The project demonstrates potential of Antiverse’s platform to reduce time and costs associated with antibody drug discovery.
H.E.L Group appoints Rajeev Kumria as General Manager of H.E.L India
Experienced General Manager and commercial leader will scale H.E.L's operations in Indian growth markets, including biotechnology, process safety, and pharmaceutical industries. The appointment will enable H.E.L India to provide direct sales and marketing, service, and support operations to customers locally.
Avacta selects second pre|CISION™ pro-drug candidate for development
Cambridge and Wetherby, UK: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces that the next pre|CISION™ drug candidate, AVA3996, has been selected for pre-clinical development with a view to a first-in-human Phase I clinical trial beginning…
Insightful Science acquires Omiq to add cloud-based machine learning to its flow cytometry capabilities
OMIQ is a powerful flow cytometry SaaS solution adopted by leading global biopharma labs.
The Native Antigen Company expands range of Norovirus-like particles
Oxford, UK: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, has announced the expansion of its norovirus-like particle range, with the addition of six new reagents, including four which are unique to the market. These virus-like…
NeoCura and PhoreMost announce research collaboration to explore novel cancer therapeutics
Shenzhen, China and Cambridge, UK: NeoCura Bio-Medical Technology Co., Ltd. (“NeoCura”), a leading RNA-based drug research and development company in China, and PhoreMost Limited (PhoreMost), the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’, have announced an oncology drug discovery research collaboration.
H.E.L Group expands operations in India
H.E.L India opening further strengthens H.E.L's global presence with regional hub-based service and customer support. Expansion will focus on supporting high growth industries in India, including biotechnology, process safety, and pharmaceutical industries
Avacta provides update on AffiDX® SARS-CoV-2 antigen lateral flow test and detection of the Omicron variant
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, provides an update on the performance of the AffiDX® SARS-CoV-2 antigen lateral flow test (LFT) with the Omicron variant.